UPPSALA, Sweden, May 06, 2004 (PRIMEZONE) --
-- Turnover for the first quarter of 2004 amounted to SEK 179.7 (141.3) million, which is an increase of 27 percent.
-- Operating income amounted to SEK -2.5 (4.7) million, excluding the item affecting comparability for 2003.
-- Net income after tax amounted to SEK 3.8 (2.8) million, excluding the item affecting comparability for 2003.
-- Earnings per share amounted to SEK 0.16 (19.20).
-- RESTYLANE SubQ approved for sales in Europe.
-- DUROLANE approved for the treatment of osteoarthritis of the hip joint in Europe.
-- A study on patients with fecal incontinence begun.
Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces and markets medical implants. All products are based on the company's patented NASHA technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Q-Med today has 480 employees, with approximately 310 at the company's production facility and head office in Uppsala. The Q-Med share is listed on the Attract 40 list of the Stockholm Stock Exchange.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/05/06/20040506BIT20880/wkr0006.pdf
Dowload report as PDF-file